December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

26.78 -0.48 (-1.76%)
Streaming Delayed Price Updated: 3:29 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Expert Ratings For ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Recap: ACADIA Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals ↗
 
Via Benzinga
News headline image
3 Pharma Stocks to Sell in March Before They Crash & Burn ↗
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why Are Airline Stocks Down Today? ↗
Airline stocks are down on Tuesday as investors deal with several bits of bad news for the industry on Tuesday! 
Via InvestorPlace
News headline image
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? ↗
Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin. 
Via InvestorPlace
News headline image
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
News headline image
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study ↗
The company says it doesn't plan to further develop Nuplazid in clinical testing. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fis 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday! 
Via InvestorPlace
News headline image
Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details ↗
Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations. 
Via Benzinga
News headline image
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
3 Stock Winners That Are Up 1,000% or More in 2024 ↗
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
News headline image
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch ↗
CEO Steve Davis said there was a lot of pent-up demand when Daybue first launched last year. 
Via Investor's Business Daily
News headline image
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
News headline image
Acadia Announces Additions to Executive Team
From Acadia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.